Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting

Hisashi Matsubara1, Yoshitsugu Matsui1, Ryohei Miyata1, Atsushi Ichio2, Shinichiro Chujo1, Hiroko Enomoto1, Masahiko Sugimoto1, Mineo Kondo1

Abstract

Purpose To investigate the outcomes of a suspension of anti-vascular endothelial growth factor (anti-VEGF) treatments in the eyes with neovascular age-related macular degeneration (nAMD).

Methods This was a retrospective study that examined eyes having no exudation for 48 weeks while undergoing intravitreal anti-VEGF injections every 12 to 16 weeks. The rate and time of recurrences, best-corrected visual acuity (BCVA), central subfield thickness (CST), number of visits, and reactivity to anti-VEGF were determined after the suspension of the anti-VEGF treatments.

Results In 34 eyes of 34 patients, 17 eyes (50.0%) had a recurrence during the 24-month follow-up period. The median time of a recurrence was 10 months. The BCVA was maintained for 24 months after the suspension regardless of the development of any recurrences. In 41.7% of the eyes that resumed treatment, the duration of exudation suppression by the anti-VEGF therapy was shorter than 12 weeks during the 12 months after restarting the anti-VEGF treatments. There was a significant increase in the number of visits during the first year after beginning the suspension versus during the 1 year before the suspension (non-recurrence group; \( P = 0.007 \), recurrence group; \( P = 0.001 \)).

Conclusion Although one-half of the eyes had a recurrence within 24 months after a suspension of anti-VEGF treatment, the BCVA was maintained after a resumption of the anti-VEGF treatments. However, the number of hospital visits increases regardless of the recurrences and the lesion stability is altered by the anti-VEGF suspension. Clinicians should explain both the advantages and disadvantages of anti-VEGF suspension to nAMD patients.

Keywords Age-related macular degeneration · AMD · Anti-VEGF agents · Intravitreal injection · Treatment suspension · Recurrence · Number of hospital visits
Introduction

Age-related macular degeneration (AMD) is a major cause of vision reduction in the elderly, and it is feared that the number of cases will increase worldwide in the near future [1]. In Japan, there has been an increase in the number of patients with neovascular AMD (nAMD) in conjunction with the increase in the elderly population and westernization of their lifestyle [2, 3]. Today, intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have become the first-line therapy for nAMD. Several early nAMD clinical trials have shown that monthly or bimonthly injections of anti-VEGF agents were effective in improving and maintaining the visual acuity [4–6]. However, the need of monthly or bimonthly intravitreal injections imposed a heavy economic and physical burden on the individuals. On the other hand, treat and extend (TAE) regimen, in which the treatment interval is changed depending on the status of the retinal lesions, can reduce the burden on patients by decreasing the cost, number of injections, and hospital visits, with an improvement in the visual acuity [7, 8]. Moreover, to reduce the burden of the intravitreal injections, guidelines for the suspension of the anti-VEGF injections in eyes with nAMD with milder lesion activity have been proposed [9, 10]. In contrast, there is another proposal that these treatments should be continued to maintain the effects of the anti-VEGF treatments [11]. Thus, at present, it remains unclear as to whether suspension of anti-VEGF is effective in reducing the burden while maintaining the efficacy of the treatments. Thus, the purpose of this study was to evaluate the rate of recurrences and the degree of exudations in eyes with nAMD which matched the anti-VEGF suspension criteria, regardless of any past intravitreal injection treatment history. This study also examined the visual and anatomical outcomes and the changes in the number of hospital visits after the suspension of the anti-VEGF treatments.

Materials and methods

Study design

The procedures used were approved by the Ethics Committee of Mie University Hospital (approval number. H2020-021), and they conformed to the tenets of the Declaration of Helsinki. The medical records of nAMD patients who were treatment naïve and had started the treatment of the nAMD by intravitreal injections of ranibizumab (Lucentis; Novartis, Bulach, Switzerland) or aflibercept (Eylea; Bayer, Basel, Switzerland) between April 1, 2009, and December 31, 2018, at the Mie University Hospital, Mie, Japan, were reviewed.

Inclusion and exclusion criteria

Patients were included if they were (1) > 50 years of age, (2) had been diagnosed and treated by intravitreal injections of ranibizumab or aflibercept for more than 2 years at the Mie University Hospital, (3) subsequently treated by the TAE regimen or the fixed dosing regimen, (4) agreed to the suggestion of treatment suspension, and (5) met the “suspension criteria.” The “suspension criteria” was defined as the absence of exudations or hemorrhages for at least 48 weeks with continuous anti-VEGF treatment every 12 to 16 weeks. Patients were excluded if they had photodynamic therapy, laser photocoagulation in the macular region, prior vitrectomy or intravitreal injection of steroids in the targeted eye, or had been treated in both eyes by an anti-VEGF agent during the study period for any retinal disease.

Data acquisition

The beginning of the treatment suspension was defined as the visit when the last anti-VEGF injection was given during the “suspension criteria” period (baseline). The recurrence point was defined as the visit when subretinal fluid (SRF),
intraretinal fluid (IRF), or retinal hemorrhage was detected by optical coherence tomography (OCT) or fundus examinations. The demographic and clinical features extracted from the medical records included the age, sex, past treatment periods (months), number of past anti-VEGF injections at the baseline, subtype of AMD, e.g., typical AMD or polypoidal choroidal vasculopathy (PCV), and the greatest linear dimension (GLD) of the lesion at the time of first diagnosis. The decimal best-corrected visual acuity (BCVA) and central subfield thickness (CST) were measured in all eyes at each visit. The pretreatment subtype of AMD was determined from the fluorescein and indocyanine green angiographic images. The CST was the average thickness in the central 1 mm, and it was measured as the distance between the internal limiting membrane and Bruch’s membrane in the OCT images.

Post-suspension follow-up methods and treatment regimens

After the suspension of anti-VEGF treatments, the status of the lesion was monitored by OCT, fundus examinations, and BCVA measurements at each visit. The first visit after the suspension was at 3 months, and the subsequent visits were to our hospital or nearby clinic was every 1 to 2 months during the first year after the suspension. During the second year, the visit interval was decided on by the treating ophthalmologist, and the patients were examined every 2 to 4 months. This interval was continued until a recurrence occurred. In all eyes in which the anti-VEGF treatment was resumed, the presence of exudation was assessed at 1 month after the resumption. The treatment regimen used after the resumption was selected by the treating ophthalmologist.

Number of hospital visits

The number of visits to the Mie University Hospital for the purpose of evaluation and treatment for the nAMD was counted during the following periods: (1) 1 year before the baseline (Pre 1 year), from the closest visit 12 months prior to the baseline to baseline, (2) the first year after suspension (Year 1), from the next visit after the baseline to the closest visit 12 months after the baseline, and (3) the second year after suspension (Year 2), from the next visit after the last visit in Year 1 to the closest visit 24 months after the baseline.

Statistical analyses

The descriptive data are presented as numbers, percentages, medians with the first and third quartiles (Q1, Q3), and the 95% confidence intervals (CIs) when appropriate. The rate and recurrence times were analyzed using the Kaplan–Meier method. Cox proportional hazard regression analysis was performed to estimate the hazard ratio for the recurrences by univariate and multivariate analysis and included the age, sex, subtype of AMD, and past treatment period prior to the suspension. The selection of priori variables was based on the data in past publications [12, 13], the result of univariate analyses, and clinical perspectives. For statistical analyses, Mann–Whitney’s U test, Fisher’s exact tests, the Wilcoxon matched pairs signed-rank tests, and the Friedman tests with a post-hoc Dunn test were used. The decimal BCVA was converted to the logarithm of the minimum angle of resolution (logMAR) units for statistical analyses. All P values were two sided and a P < 0.05 was taken to be statistically significant. A Cox proportional hazard regression analysis was performed using the IBM SPSS Statistics Desktop (version 26; IBM Japan, Tokyo, Japan). Other statistical analyses were performed using Prism 8 software (GraphPad, Inc., La Jolla, CA, USA).

Results

Baseline characteristics

Of the 385 patients whose medical records were examined, there were 34 eyes of 34 patients who met the inclusion criteria (Fig. 1). These included 12 females and 22 males whose median age was 76 years. The baseline characteristics of the patients are presented in Table 1. Of the 34 eyes, there were 21 eyes with typical AMD and 13 eyes with PCV. The median of the past treatment period was 39 months, and the median number of the past treatments was 14. A recurrence was found in 17 (50.0%) of the 34 eyes. The type of fluid in recurrent cases was SRF in 9 cases, IRF in 2 cases, both SRF and IRF in 4 cases, and retinal hemorrhage in 2 cases. Only the past injection numbers were significantly different between the non-recurrence and recurrence groups (P = 0.0451; Table 1).

Recurrence rates and time points

By determining a recurrence by OCT at short intervals after the suspension, recurrences were detected on a monthly basis in most cases. Of the 34 eyes, 13 eyes (38.2%) had a recurrence within 12 months and 4 eyes (11.8%) had a recurrence within 13 to 24 months after the suspension of the anti-VEGF treatments (Fig. 2). Thus, 13 of the 17 eyes (76.5%) had the recurrence occurring within 12 months. The median (Q1, Q3) time to recurrence after the treatment suspension was 10 (6, 12) months. The results of the Cox proportional hazard model are shown in Table 2. There were no factors that were significantly associated with the recurrence (P = 0.181).
Changes of best-corrected visual acuity (BCVA) and central subfield thickness (CST)

The BCVA and CST for both subgroups at the baseline, at the time of a recurrence, and at 24 months after the suspension are shown in Table 3. The data for all 17 eyes with a recurrence are shown in Table 4. The BCVA did not change significantly in either subgroup (non-recurrence group, \( P = 0.424 \); recurrence group, \( P = 0.687 \)). However, 2 eyes (cases #9 and #16) in the recurrence group had a worsening of the BCVA by > 0.20 logMAR units due to residual IRF in the macular lesion with and without treatment resumption. The CST in the recurrence group was significantly thicker at the time of the recurrence (\( P < 0.0001 \)), and the thickness had recovered at 24 months after the suspension (\( P = 0.154 \)).
Response to anti-VEGF agents after resumption

Of the 12 eyes that completed the 12 months of follow-up after the resumption of anti-VEGF treatments, 6 eyes were treated with a 12-week fixed regimen, 3 eyes had the TAE regimen starting at 12-week intervals, 1 eye underwent TAE starting at 16-week intervals, and 2 eyes underwent the pro re nata (PRN) regimen. The exudation disappeared in all of the resumed cases at 1 month after the resumption. However, in 5 of 12 (41.7%) eyes, the exudation suppression was not sustained for at least one 12-week period during the 12 months after the resumption.

Number of visits before and after treatment suspension

The number of visits before and after the suspension is shown in Fig. 3. In both subgroups, the number of visits was significantly increased between the Pre 1 year and Year 1 (non-recurrence group, \( P = 0.007 \); recurrence group, \( P = 0.001 \)), but there were no significant differences between Pre 1 year and Year 2 (non-recurrence...
In contrast, the number of visits during Year 2 in the recurrence group was significantly greater than that for the non-recurrence group ($P = 0.016$). The 6 eyes in the recurrence group with 8 or more visits during Year 2 had recurrences at 7, 12, 13, 15, 18, and 19 months after the suspension.

### Number of injections that was reduced due to suspension of anti-VEGF treatments

The number of injections that was reduced by the suspension was calculated using the dosing interval during the “suspension criteria” period and the recurrence time points. The median (Q1, Q3) number of injections that were reduced for all eyes was 5 (3, 8), for the non-recurrence group was 8 (6, 8), and it was 3 (2, 4) for the recurrence group.

### Discussion

Our study was designed for real-world clinical conditions, and the findings showed that the rate of recurrences of exudation was 38.2% for 12 months and 50.0% for 24 months after the treatment suspension. There were no statistically significant factors that could be used to predict the time of the recurrence. In contrast, the BCVA was maintained for 24 months after the immediate resumption of the anti-VEGF treatment in the recurrence cases. We also gained a new insight that there was a significant increase in the number of hospital visits during the first year after the suspension regardless of whether an exudation recurred.

A suspension of the anti-VEGF treatment in eyes with nAMD has been proposed as part of the treatment protocol [9, 10] or the TAE regimen [12, 14–16]. Earlier studies reported that the rate of recurrence was 13.0 to 52.9% after an interruption of anti-VEGF treatment under the TAE regimen [12, 14–16]. In our study, we found a similar high recurrence rate after suspension of the intravitreal anti-VEGF treatments. These results indicated that it is necessary to monitor the treatment-suspended eyes with a careful search for recurrences because a stabilization of choroidal neovascularization (CNV) is not sustained in many cases. Moreover, several other studies have reported that the majority of recurrences occurred during the first year after the suspension [12–14] with a percentage as high as 50% [13, 14]. Our study also found that 76.5% of recurrences occurred during the first year after the suspension. Another result of this study indicated that recurrences occurred at an almost constant rate during the first year after the suspension. However, it should be noted that follow-up examinations were performed every 2 to 4 months in the earlier studies [12, 14, 15]. The eyes in our study were assessed for recurrence at

![Table 3](image-url)
Table 4 Characteristics of patients with eyes exhibiting recurrence

| No | Sex | Age | Subtype of AMD | Past treatment | Within the suspension criteria period | After the recurrence | For 12 months after the resumption | BCVA (logMAR) |
|----|-----|-----|----------------|---------------|---------------------------------------|----------------------|-----------------------------------|--------------|
|    |     |     |                |               | Period (months) | IVI numbers | VEGF agent | IVI interval (weeks) | Recurrence (months) | IVI resumption | Treatment regimen | F/U Complete suppression | Baseline Recurrence | 24 months after the suspension | 12 months after the resumption |
| 1  | M   | 77  | tAMD           |               |             |            | A         | 12               | 3                  | Yes           | FIX (12 weeks)       | Yes                     | No                     | 0.22                  | 0.22                  | 0.52                  | 0.30                  |
| 2  | M   | 69  | tAMD           |               |             |            | A         | 12               | 4                  | Yes           | FIX (12 weeks)       | Yes                     | Yes                    | 0.22                  | 0.22                  | 0.30                  | 0.30                  |
| 3  | M   | 86  | tAMD           |               |             |            | A         | 12               | 4                  | Yes           | FIX (12 weeks)       | Yes                     | No                     | 0.40                  | 0.40                  | 0.40                  | 0.40                  |
| 4  | F   | 80  | PCV            |               |             |            | A         | 12               | 5                  | Yes           | TAE (12 weeks ~)     | Yes                     | Yes                    | 0.10                  | 0.22                  | 0.046                 | 0.046                 |
| 5  | M   | 79  | PCV            |               |             |            | A         | 12               | 6                  | Yes           | PRN                                        | Yes                     | Yes                    | 0.00                  | 0.00                  | 0.00                  | 0.097                 |
| 6  | M   | 64  | PCV            |               |             |            | A         | 12               | 6                  | Yes           | FIX (12 weeks)       | Yes                     | Yes                    | 0.16                  | 0.16                  | 0.22                  | 0.22                  |
| 7  | F   | 81  | tAMD           |               |             |            | R         | 12               | 7                  | Yes           | TAE (12 weeks ~)     | Yes                     | Yes                    | 0.00                  | 0.00                  | -0.079               | 0.00                  |
| 8  | M   | 74  | PCV            |               |             |            | A         | 12               | 9                  | Yes           | FIX (12 weeks)       | Yes                     | Yes                    | 0.30                  | 0.30                  | 0.16                  | 0.16                  |
| 9  | F   | 82  | tAMD           |               |             |            | R         | 12               | 10                 | No            | -                                                      | No                      | -                      | 0.82                  | 1.3                   | 1.7                   | -                     |
| 10 | M   | 72  | PCV            |               |             |            | A         | 16               | 11                 | Yes           | TAE (16 weeks ~)     | Yes                     | Yes                    | 0.00                  | 0.10                  | -0.079               | -0.079                |
| 11 | M   | 87  | PCV            |               |             |            | A         | 12               | 11                 | Yes           | TAE (8 weeks ~)      | No                      | -                      | 0.22                  | 0.30                  | -                     | -                     |
| 12 | M   | 83  | PCV            |               |             |            | A         | 16               | 12                 | Yes           | TAE (12 weeks ~)     | Yes                     | No                     | 0.16                  | 0.22                  | 0.22                  | 0.22                  |
| 13 | M   | 88  | tAMD           |               |             |            | A         | 12               | 12                 | No            | -                                                      | No                      | -                      | 0.22                  | 0.52                  | 0.30                  | -                     |
| 14 | F   | 66  | tAMD           |               |             |            | R         | 12               | 13                 | Yes           | PRN                                        | Yes                     | Yes                    | -0.079                | -0.08                 | 0.00                  | -0.079                |
| 15 | M   | 91  | tAMD           |               |             |            | A         | 12               | 15                 | Yes           | PRN                                        | No                      | -                      | 0.22                  | 0.22                  | -0.30                 | -                     |
| 16 | M   | 79  | tAMD           |               |             |            | R         | 12               | 18                 | Yes           | FIX (12 weeks)       | Yes                     | No                     | -0.079               | 0.22                  | 0.16                  | 0.16                  |
| 17 | M   | 76  | tAMD           |               |             |            | A         | 16               | 19                 | Yes           | TAE (8 weeks ~)      | No                      | -                      | 0.22                  | 0.16                  | 0.22                  | -                     |

**Complete suppression** complete suppression of exudation for 12 weeks

**AMD** age-related macular degeneration, **tAMD** typical age-related macular degeneration, **PCV** polypoidal choroidal vasculopathy, **IVI** intravitreal injection, **VEGF** vascular endothelial growth factor, **F/U** follow-up, **BCVA** best-corrected visual acuity, **logMAR** logarithm of the minimum angle of resolution, **F** female, **M** male, **A** aflibercept, **R** ranibizumab, **TAE** treat and extend, **PRN** pro re nata
1- to 2-month intervals which is a closer interval compared to the earlier reports. Another study reported that the duration of VEGF suppression by anti-VEGF drugs varied from case to case [17]. Therefore, the discontinuation of the anti-VEGF drugs may have led to a recurrence at a time when the VEGF suppression was lost in these cases. As a result, variations in the timing of the recurrence could have caused this constant rate of recurrences which could be detected by our detailed evaluations. These results are similar to that of an earlier prospective study that used bimonthly follow-up examinations [12]. These findings along with those of the previous studies suggested that continuous and close follow-ups are required for at least 1 year after the suspension of the anti-VEGF treatments.

The BCVA was maintained for 24 months after the suspension regardless of recurrences which is similar to previous reports [14–16]. It is well known that the improvement of the BCVA in cases where the timing of the intravitreal injection of anti-VEGF agent is delayed can be difficult when exudation was present [18]. Therefore, the early detection of recurrences and the appropriate timing of the anti-VEGF injections are important factors in being able to maintain the BCVA. In the current study, it was possible to detect a recurrence earlier by our shorter intervals of evaluations. Based on these results, early therapeutic resumption of anti-VEGF treatment might be an effective way to maintain the BCVA in recurrence cases. However, it is similar to an earlier report that pointed out that the visual acuity reduction can occur in some cases regardless of the resumption of treatment [14]. For example, there was one eye that had a worsening of the visual acuity due to residual IRF in the macular region despite the resumption of the anti-VEGF treatment. The reasons for this may be associated with the change in the response to the anti-VEGF agent or inadequate treatment after the resumption. In our study, the short-term anti-VEGF response to the lesion was good and remained unchanged due to the absence of exudation at 1 month after the resumption in all resumed eyes. In contrast, the long-term drug responsiveness could have been altered because in 5 of 12 eyes (41.7%), the suppression of the exudation was not completely sustained for 12 weeks during the 12 months after the resumption of intravitreal anti-VEGF injections. These results suggest that the duration of the exudation inhibition was alterable under the anti-VEGF suspended conditions as compared to that observed before the suspension. Earlier studies have reported that the lesion activity was constant after 2 to 3 years of starting anti-VEGF treatments [13, 19], and the treatment interval was not changed during a long follow-up period when under continuous treatment [20]. All 5 eyes in this study were treated for more than 2 years prior to the suspension of anti-VEGF treatments. However, VEGF was not suppressed by the anti-VEGF suspension. As a result, the persistent lack of VEGF suppression might have led to an increase in the disease activity. Although the treatment regimen after resumption will likely affect the subsequent outcomes, the optimal retreatment regimen has yet to be definitively determined. In earlier studies, the TAE regimen was restarted after 2 or 3 monthly anti-VEGF injections [14, 15]. However, the eyes evaluated in our study were treated with various regimens after resuming the anti-VEGF treatments. Thus, the visual acuity of recurrence eyes had not deteriorated at the time of the recurrence and in all recurrence eyes exudation had completely disappeared at 1 month after the resumption of the treatments. These results may have led the treating doctors to judge that the disease activity was as low as at the time of suspension and that monthly dosing was not necessary. In 5 eyes that had unsatisfactory exudation control, 3 eyes were retreated with a 12-week fixed regimen while 2 underwent TAE restarting at the 12-week intervals. Thus, there is a possibility that the treatment during the early stages after the recurrence was inadequate. Therefore, to reduce and control the exudation quickly, it may be better to restart treatments with several consecutive monthly doses followed by the TAE regimen.

Although the number of visits represents one of the burden factors, there has been no study that has evaluated the number before and after the suspension of anti-VEGF treatments. Monthly evaluations are desirable after the
suspension to detect recurrences earlier because the treatment regimen is changed from the proactive regimen to the PRN regimen. Therefore, the eyes evaluated in this study were assessed for recurrences at the shortest possible interval. As a result, the number of visits could have been significantly increased during Year 1 as compared to that at Pre 1 year regardless of recurrences. In contrast, during Year 2, the number of visits could have decreased because the follow-up interval in the non-recurrence eyes was extended because there were no recurrences for 1 year and also because the treatment was resumed in the recurrence eyes and continued with a long interval regimen in most of the eyes with a recurrence. However, in Year 2, there were a larger number of visits for the recurrence group than the non-recurrence group due to the recurrence cases that occurred and resumed during Year 2. Based on these results, the preferred follow-up period after the suspension would be a monthly evaluation during the first year, with the second year visit interval based on the first year results. The rationale for this method is to detect recurrence early so that treatment can be resumed even if more visits are required.

All of the results demonstrated the necessity of considering the advantages and disadvantages of suspending the anti-VEGF treatments. The advantages of suspension are the reduction in the treatment cost and the risk of complications that can occur from repeated intravitreal injections. Our results showed that it was possible to avoid a median of 8 anti-VEGF injections in our non-recurrence group over 2 years. In contrast, the disadvantages included the possibilities of visual acuity reduction, requirement of shorter dosing intervals after the resumption, and an increase of the number of hospital visits. Moreover, it has been reported that 79% of cases were reactivated within 5 years after a treatment suspension [13]. Therefore, recurrences are likely to occur over a long period of time in most cases, and thus, there is a limit to the number of intravitreal injection treatments that can be reduced. Appropriate considerations of each case are required as the advantages and disadvantages might be different for each case.

**Limitations**

The limitations of this study include the small sample size and the retrospective design. In addition, this study included cases in which the treatment regimens were changed to proactive regimens due to higher levels of lesion activity even if initiated with the PRN regimen. Therefore, it is possible that the CNV lesion activity might not have been lower. In addition, the study design had a selection bias as patients who agreed to the suggestion of treatment suspension were included in the analyses. Therefore, the enrolled participants in this study were not selected purely on the basis of disease activity. There was also a limitation with regard to the standardization of the treatment regimen before and after suspension of the anti-VEGF treatments because this was a retrospective study. As a result, our overall outcomes might not be representative. Despite the above limitations, the results may be helpful in making decisions for intravitreal injection suspension in the real-world clinical practice.

**Conclusions**

In conclusion, the findings demonstrate that one-half of the eyes that met the “suspension criteria” had a recurrence within 2 years. Thus, treatment suspension had both good and bad outcomes. Therefore, clinicians need to fully explain both possibilities to patients when anti-VEGF treatment suspension is being considered. Further research is required to assess the long-term outcomes of the anti-VEGF suspension in patients with nAMD in the real-world clinical setting.

**Acknowledgements** The authors thank Professor Duco Hamasaki of the Bascom Palmer Eye Institute of the University of Miami for critical discussion and final manuscript revisions.

**Author contribution** HM: conception of the study, collection and interpretation of data, drafting of the manuscript. HE, SC, and AI: collection and assembly of data. YM and RM: analysis of data and manuscript review. MS: manuscript review. MK: manuscript review and final approval.

**Declarations**

**Ethics approval** The procedures used conformed to the tenets of the Declaration of Helsinki of the World Medical Association. All protocols were reviewed and approved by the Ethics Committee of Mie University Hospital (approval number: H2020-021).

**Consent to participate** This retrospective study involves de-identified patient data, and the IRB of the Mie University Hospital approved to waive the written informed consent.

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106-116

2. Oshima Y, Ishibashi T, Murata T et al (2001) Prevalence of age-related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol 85:1153–1157

3. Yasuda M, Kiyohara Y, Hata Y et al (2009) Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population. Ophthalmology 116:2135–2140

4. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

5. Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65

6. Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548

7. Wykoff CC, Ou WC, Brown DM et al (2017) Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD Study. Ophthalmol Retina 1:314–321

8. Ohji M, Takahashi K, Okada AA et al (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther 37:1173–1187

9. Koh A, Lanzetta P, Lee WK et al (2017) Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel. Asia-Pac J Ophthalmol 6:296–302

10. Ross AH, Downey L, Devonport H et al (2020) Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond) 34:1825–1834

11. Khurana RN (2019) Long-term management of neovascular age-related macular degeneration: to suspend or not to suspend? Ophthalmol Retina 3:621–622

12. Aslanis S, Amrén U, Lindberg C et al (2021) Recurrent neovascular age-related macular degeneration after discontinuation of VEGF inhibitors managed in a treat and extend regimen. Ophthalmol Retina Online ahead of print

13. Nguyen V, Vaze A, Fraser-Bell S et al (2019) Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Ophthalmol Retina 3:623–628

14. Adrean SD, Chaili S, Grant S et al (2018) Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a Treat-Extend-Stop Protocol. Ophthalmol Retina 2:225–230

15. Munk MR, Arendt P, Yu S et al (2018) The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with Exit Strategy. Ophthalmol Retina 2:288–294

16. Arendt P, Yu S, Munk MR et al (2019) Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina 39:27–33

17. Fauser S, Schwabecker V, Muether PS (2014) Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 158:532–536

18. Richard G, Monés J, Wolf S et al (2015) Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology 122:2497–2503

19. Traine PG, Püister IB, Zandi S et al (2019) Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina 3:393–399

20. Invernizzi A, Nguyen V, Teo K et al (2019) Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. Am J Ophthalmol 204:105–112

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.